Work

Anti-VEGF Therapy and the Retina: An Update

Year: 2015
Type: review
Abstract: Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.
Language: English
Subfield: Ophthalmology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,040
OpenAlex ID: W1563094820
FWCI: 2.029
Cites: 87
Cited by: 139
Related to: 9